PANCURONIUM BROMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PANCURONIUM BROMIDE (PANCURONIUM BROMIDE).
Competitive antagonist of nicotinic acetylcholine receptors at the neuromuscular junction, preventing acetylcholine from binding and thus inhibiting muscle contraction.
| Metabolism | Primarily excreted unchanged in urine (60-80%); minor hepatic metabolism via deacetylation. |
| Excretion | Renal: 50-70% unchanged; biliary/fecal: 5-10% as metabolites; minor hepatic metabolism. |
| Half-life | Terminal elimination half-life: 100-120 minutes in adults with normal renal function; prolonged to 240-480 minutes in renal failure. |
| Protein binding | ~30-40% bound, primarily to albumin and to a lesser extent to gamma-globulins. |
| Volume of Distribution | Vd: 0.15-0.3 L/kg; reflects distribution primarily in extracellular fluid and limited tissue binding. |
| Bioavailability | IV: 100%; oral: negligible (<1%) due to poor absorption and first-pass metabolism; IM: not used clinically. |
| Onset of Action | IV: 3-5 minutes for intubating doses (0.08-0.1 mg/kg); IM: not recommended due to unreliable absorption. |
| Duration of Action | IV: 60-90 minutes for initial doses; recovery to 25% twitch height ~60 min; cumulative with repeated doses; prolonged in hepatic/renal impairment. |
| Action Class | Skeletal muscle relaxant- Peripherally acting |
| Brand Substitutes | Panuron 2mg Injection, Pavulon 2mg Injection |
0.04-0.1 mg/kg IV initial bolus, then 0.01-0.02 mg/kg IV every 20-40 min as needed for neuromuscular blockade.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: no dosage adjustment required but prolonged effect may occur; GFR <10 mL/min: reduce dose by 50% and monitor neuromuscular function closely. |
| Liver impairment | Child-Pugh A/B: no dosage adjustment required; Child-Pugh C: reduce initial dose by 25-50% and monitor closely due to prolonged elimination. |
| Pediatric use | Neonates: 0.02-0.04 mg/kg IV initial, maintenance 0.01-0.02 mg/kg every 30-60 min; Infants: 0.04-0.08 mg/kg IV initial, maintenance 0.01-0.02 mg/kg every 30-60 min; Children: 0.06-0.1 mg/kg IV initial, maintenance 0.01-0.02 mg/kg every 20-40 min. |
| Geriatric use | Lower initial dose (0.03-0.06 mg/kg IV) is recommended due to slower clearance and increased sensitivity; adjust subsequent doses based on neuromuscular monitoring. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PANCURONIUM BROMIDE (PANCURONIUM BROMIDE).
| Breastfeeding | Pancuronium excretion into breast milk is likely negligible due to its high polarity and large molecular size. A milk-to-plasma (M/P) ratio has not been established but is expected to be very low. The American Academy of Pediatrics considers pancuronium compatible with breastfeeding, though caution is advised in neonates with compromised renal function. Limited data suggest minimal infant exposure. |
| Teratogenic Risk | Pancuronium bromide is a quaternary ammonium neuromuscular blocker that does not cross the placenta in significant amounts due to its high polarity and molecular weight. Animal studies have not shown teratogenic effects. In humans, no evidence of teratogenicity has been reported, but data are limited. During the first trimester, theoretical risk is low. In second and third trimesters, administration for maternal indications (e.g., intubation) is considered acceptable when necessary, though fetal monitoring is advised. Placental transfer is minimal, but close monitoring for fetal heart rate and uterine tone is recommended during administration near delivery. |
■ FDA Black Box Warning
Should be administered only by adequately trained individuals familiar with its actions, characteristics, and hazards. Facilities for intubation, artificial respiration, oxygen therapy, and reversal agents must be immediately available.
| Serious Effects |
["Hypersensitivity to pancuronium or bromide ions","Tachycardia or conditions where tachycardia is dangerous (e.g., coronary artery disease)","Myasthenia gravis","Pre-existing pulmonary hypertension"]
| Precautions | ["Prolonged neuromuscular blockade due to accumulation in renal impairment","Risk of anaphylactic reactions","Concurrent use with halogenated anesthetics may potentiate blockade","Requires monitoring of neuromuscular function with a nerve stimulator"] |
Loading safety data…
| Fetal Monitoring | Maternal monitoring: continuous ECG, blood pressure, oxygen saturation, and neuromuscular function (train-of-four or twitch monitoring) during use. Fetal monitoring: continuous fetal heart rate and uterine activity monitoring when used during pregnancy or near delivery. Assess for fetal bradycardia or changes due to maternal hypotension from concurrent anesthesia. |
| Fertility Effects | No specific studies on human fertility exist. Pancuronium is not expected to impact fertility due to its peripheral site of action; it does not cross the blood-testis barrier or affect oocyte or sperm function significantly. No adverse reproductive effects were noted in animal studies at clinical doses. |